News & Updates
Greffex Receives Notice from the National Eye Institute/NIH to Begin Gene Therapy Work on Usher Syndrome Blindness
In the fall of 2020, Greffex was awarded an NIH contract to develop a gene therapy to address Usher Syndrome blindness. According to Greffex CEO, John Price, “Greffex is excited to continue its mission to provide hope to children and families who have been dealt a harsh hand. Usher Syndrome affects both hearing and vision loss in children and young adults to varying degrees. It is a hereditary disease with no current cure, however, Greffex will deploy its gene therapy expertise in hopes of preventing the blindness aspect of Usher.”
Chief Scientific Officer, Dr. Uwe Staerz, and his team in Aurora, Colorado will lead the studies which they will commence on March 1, 2021.
In addition to its work on Usher Syndrome, Greffex is continuing to accelerate its vaccine program, with two vaccine candidates in pre-clinical trials – a Covid-19 vaccine and an H5N1 avian influenza vaccine – and a third vaccine candidate for universal flu nearing pre-clinical stage later in 2021.
January 29, 2021
Greffex presented unofficial pre-clinical trial data this week on its H5N1 vaccine candidate that it’s been working to develop under an NIH contract.
Early results are encouraging. 100% of the mice that received the Greffex H5N1 vaccine survived after being challenged with a lethal dose of H5N1. Conversely, 100% of the mice that were not vaccinated died or were euthanized in less than a week for having lost excessive body weight. Even the mice that received a single dose and a low dosage had 100% survival.
In addition to the survival tests the Greffex trials revealed strong T-cell and strong antibody responses, well in excess of the FDA requirements. While more animal trials will be conducted in the near term, these early results are consistent with highly immunogenic results from previous tests sponsored by the NIH on Greffex’s H5N1 and MERS vaccines.
January 10, 2021
Greffex, a pioneering vaccine and gene therapy company with a lab in Aurora, Colorado and headquartered in Houston, Texas began pre-clinical trials this week on its Covid-19 monovalent vaccine.
This is the first step in Greffex’s Covid-19 pre-clinical trials which will subsequently involve trials for its bi-valent and tri-valent Covid-19 vaccine candidates. Greffex’s Covid-19 vaccine will come in a single dose, will not require a freezer for storage, and will be multi-valent by presenting the Spike, M and N proteins or some combination, making for a more durable vaccine better equipped to handle mutations.
Core to the Greffex vaccine platform is its patented fully-deleted helper independent adenoviral vector technology which improves upon early generation Ad vectors. In addition, Greffex will base its vaccine on the rare human serotype Ad6. Taken together, these scientific advancements should translate to cleaner, safer, more effective and durable vaccines.
Houston, Tx. June 4th 2020
Greffex, a pioneering vaccine and gene therapy company based in Houston, Texas, welcomes Mr. Neil Bush to its Board of Directors.
“Neil understands the need for a global perspective to make an impact in a post pandemic world,” said Co-Chairman John Price, also President and CEO of Greffex. Mr. Bush will serve as an independent director of the company.
“The Greffex board is excited to have Neil as a part of the team. He has vast international experience with a history of knowing, and advising, the most powerful companies and leaders in the world. Neil will be a huge asset to drive our future growth and enable Greffex’s mission to create innovative therapies that protect and heal mankind,” said Price.
Bush is an international businessman who operates through Neil Bush Global Advisers. He is Chairman of Singhaiyi, a Singapore publicly listed company; Co-Chairman of CIIC, a property development business in China; and, Chairman of A&A Consulting, a global platform that provides bridging services between the United States and Asia in health care, education, and technology in the USA.
“I can think of no better way to serve”, said Bush. “I am very excited to join the Greffex board to help advance the critically important work of implementing one of the world’s first universal vaccine platforms to address the Covid-19 pandemic, and save lives, while enhancing the world’s capability to quickly respond to future pandemics. Based on testimonials of experts I am confident that Greffex will be successful — we must be successful!”
Mr. Bush also serves as Chairman of the Points of Light Board of Directors and Chairman of the Advisory Board of the Bush School of Government and Public Service. In these roles, Mr. Bush expands his father’s vision of inspiring, equipping and mobilizing volunteers to address serious social issues and training future generations of public and nonprofit leaders.
Mr. Bush will join a Board that includes:
John P Price, Greffex Co-Chairman, President and CEO
Uwe D. Staerz, M.D., Ph.D., Greffex Chief Scientist & Co-Chairman
Robert A. Eckels JD, Greffex Executive Vice President & General Counsel. Past Harris County Texas Judge William S. Connolly, Greffex Executive Vice President
Sir Walter Bodmer, PhD, FRS, Head, Cancer & Immunogenetics Laboratory, University of Oxford
Chase Untermeyer, Former US Ambassador to Qatar
Jehan A. Al-Meer, MSC, PhD, MPA, MBA, Founder and CEO of Innovation Capital Qatar R. Phil Zobrist, Real Estate Management and Development Entrepreneur
John D. White, JD., Chairman emeritus, Texas A&M University System Board of Regents
Greffex, a leading genetic engineering company, is a leader in developing a plug and play vaccine platform that delivers unprecedented time-to-market, cost efficiency, efficacy and safety through the use of proprietary clean viral vectors.
Greffex CEO, John Price’s breaking news quick interview on Texas Radio Network based out of Dallas station KRLD.
Greffex, Inc., a leading genetic engineering company, revealed its completion of a Covid-19 vaccine and is ready to move on to animal testing as required by the U.S. government Food and Drug Administration.
“This is a major development for the entire world population,” said Greffex CEO, John Price. “Greffex’s ability to scale the vaccine appropriately, test quickly and efficiently and fast track it to patients, gives us an edge over other research facilities and we’re looking forward to the next step of animal testing.”
Greffex did not use a living or killed virus for its vaccine and instead used an adenovirus-based vector vaccine, which are genetically engineered.
Once the vaccine is approved by the government, Greffex has committed free distribution of the vaccine to other countries for free.
In 2019, Greffex was awarded an $18.9 million contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. This award will enable GREFFEX to develop and exploit its GreVac(TM) Plug-And-Play Technology to expedite the production of vaccine candidates for biodefense and emerging infectious diseases to target infectious threats, whether natural or man-made.
HOUSTON, TX., September 9, 2019 — GREFFEX, INC. won a contract of up to $18.9 million with the National Institute of Health’s National Institute for Allergy and Infectious Diseases to develop and exploit its GreVac(TM) Plug-And-Play Technology to Expedite the Production of Vaccine Candidates for Biodefense and Emerging Infectious Diseases to target emerging infectious threats, whether natural or man-made.
GreVac(TM) vaccines are based upon GREFFEX’s proprietary GreGT Genetic Engineering Technology as a fast and flexible plug-and-play vaccine architecture of fully deleted helper virus- independent adenoviral vectors of rare serotypes. The proprietary GreGT platform has been built upon two independently modifiable components to provide broad gene transfer applications.
The GreVac(TM) system incorporates versatility and speed to complement and ultimately change the present paradigm of immune protection against infectious diseases with a high eruption potential from the stockpiling of potential vaccine candidates to the just-in-time production of specific vaccines.
With support by the present NIH contract, GREFFEX expects to advance the development of two of its GreVac(TM) influenza vaccines through clinical trials. The activity of a vaccine directed against a highly pathogenic avian influenza will be compared to a novel universal influenza vaccine. This research initiative is funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract HHS-NIH-NIAID-BAA2018 (BAA-2018 Omnibus Broad Agency Announcement: Research Area 2 (DMID) – Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases).
Greffex, Inc., a company leading a paradigm shift in the design, development and production of vaccines, elected two new members to its board of directors on Monday. They are John D. White, founder and chairman of PSP Capital and former U.S. Ambassador to Qatar, Chase Untermeyer. Both are accomplished leaders and will bring significant global and national experience to Greffex, Inc.
“John and Chase are both strong leaders with impressive accomplishments and contributions that span across business and public service,” said John R. Price, Co-Chairman of the Board, President and Chief Executive of Greffex, Inc. “They will serve as valuable additions to the board.”
Greffex, Inc. and the Texas A&M University System (TAMUS) are excited to announce a collaboration on advanced process and manufacturing development. This agreement will advance the research and development of Greffex vaccines and assist the Health Science Center’s Center for Innovation in Advanced Development and Manufacturing (CIADM) at TAMUS to establish a robust, efficient pipeline of countermeasures to public health emergencies both in the US and worldwide.
From the press release:
“As we prepare for the next phase of research and development, we needed a creative, innovative “university-based” partner to assist us in our long-range development plans,” said John R. Price, President and CEO of Greffex, “and in Texas A&M Health Science Center’s Center for Innovation in Advanced Development and Manufacturing (CIADM), we found the creative, forward-thinking researchers who can leverage the resources of the entire university system.”